The prevalence of human papillomavirus among women in northern Guangdong Province of China

Huang, Wenbo; Xu, Hongxing; Hu, H. M.; Zhang, Dingmei; Liu, Yulan; Guo, Yanle; Xiao, Fengjin; Chen, Weijuan; Ma, Zhihong

doi:10.1038/s41598-022-17632-y

Cited by 12 publications

(6 citation statements)

References 32 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Zhou et al’s investigation, based on an analysis of age-specified HPV infection, the observed trend revealed a decline in prevalence up to 30 years, followed by an increase until the age of 60 years [ 26 ]. Almost mirroring our findings, a study in Malaysia detected the highest HPV prevalence (11.9%) in the 18–24 age range [ 27 ], while some other studies reported a different trend with the highest prevalence (7.29%) observed in the 40–49 age group [ 28 ]. The elevated prevalence of HPV in female under 20 in our research could be attributed to the lower vaccination percentage between adolescent girls compared to adults.…”

Section: Discussionsupporting

confidence: 88%

Prevailing of HPV-16 and 52 genotype in 2022–2023 in Sanandaj, Iran

Haddadi,

Atefmehr,

Motlaghzadeh

et al. 2024

Virol J

View full text Add to dashboard Cite

Introduction Human papillomavirus (HPV) presents a potential threat to the onset of carcinogenesis in the cervix, anogenital regions, and oropharynx. HPV encompasses over 200 types, with at least 12 having the potential to cause cancer, impacting the majority of sexually active individuals. In this current research, we explore the occurrence and spread of HPV genotypes. Material and methods During this cross-sectional study conducted in Sanandaj, Iran from Feb 2022 to Aug 2023, diverse samples including oral, vaginal, and genital were collected from individuals referred to private laboratories in Sanandaj, Iran. After sample collection and DNA extraction (FAVORGEN, Taiwan), they were subjected to PCR and genotyping (MehrViru, Iran). The subsequent statistical analysis unveiled infection rates across different demographics and age groups. STATA (version 17) were used for statistical analysis. We examined infection rates across demographics using t-tests and Odds Ratio. Results Overall, 26% (249) out of 950 cases tested positive for HPV, with 69% of these classified as high-risk. Among the examined population, 98% (933) were female, and 2% (17) were male. Females aged 31–40 exhibited the highest percentage of HPV prevalence (115/460) in the study with the majority of positive cases belonging to HR genotypes. The overall most frequent genotypes identified were 6, 16, 52, 53, 51, 58, and 56. HPV-16 exhibited the highest frequency among HR genotypes, accounting for 42 (17%) occurrences, followed by HPV-52 with a frequency of 32 (13%). Conclusion Our findings emphasize the significant prevalence of HPV among females, particularly in the 21–30 age group. The identification of high-risk genotypes, underscores the importance of targeted interventions for specific age cohorts. The age-stratified analysis highlights a consistent predominance of high-risk HPV across age groups, indicating the need for age-specific preventive measures. These results contribute valuable information for designing effective screening and vaccination strategies, to alleviate the impact of diseases associated with HPV.

show abstract

Section: Discussionsupporting

confidence: 88%

Prevailing of HPV-16 and 52 genotype in 2022–2023 in Sanandaj, Iran

Haddadi,

Atefmehr,

Motlaghzadeh

et al. 2024

Virol J

View full text Add to dashboard Cite

show abstract

“…Analyzing type-specific HPV prevalence and its distribution within specific regions is a crucial component in shaping effective prevention and control strategies aimed at reducing cervical cancer rates. While many previous studies have primarily focused on HPV infection within the broader female population, only a limited number have delved into the epidemiology of HPV infection in both males and females belonging to high-risk groups (11)(12)(13)(14). Additionally, the impact of the COVID-19 pandemic on HPV prevalence has not been widely explored.…”

Section: Discussionmentioning

confidence: 99%

“…In some other regions of China, e.g., in Shanxi Province the most prevalent three genotypes were HPV16 (3%), HPV58 (1.9%) and HPV52 (0.8%) ( 17 ). In northern Guangdong Province, the most prevalent genotypes were HPV52 (4.16%), HPV16 (2.98%) and HPV58 (2.15%) ( 12 ). A survey of prevalence of HPV genotype in Yunnan Province showed that the three most prevalent genotypes were HPV52 (2.1%), HPV16 (1.7%) and HPV58 (1.0%) ( 23 ).…”

Section: Discussionmentioning

confidence: 99%

Prevalence and genotype distribution of HPV infection from Hangzhou of Zhejiang Province pre- and during COVID-19 pandemic

Wang,

Zhao,

Xia

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

Limited data exist on HPV prevalence and genotyping during the COVID-19 pandemic. A total of 130,243 samples from 129, 652 women and 591 men who visited the First People’s Hospital of Linping District between 2016 and 2022 were recruited. HPV genotypes were detected by polymerase chain reaction (PCR) amplification and nucleic acid molecular hybridization. Then the prevalence characteristics of HPV genotypes and trends in HPV infection rates from 2016 to 2022 were analyzed. Results showed that among the study population, the overall prevalence of HPV infection was 15.29%, with 11.25% having single HPV infections and 4.04% having multiple HPV infections, consistent with previous findings. HPV genotypes exhibited similar distribution patterns in both male and female groups, with HPV16, HPV52, HPV58, HPV18, and HPV39 being the most prevalent. Age-related analysis unveiled a bimodal pattern in HPV prevalence, with peaks in infection rates observed in individuals below 20 and those aged 61–65 years. Comparing the pre- and during COVID-19 periods revealed significant disparities in HPV infections, with variations in specific HPV genotypes, including 16, 18, 35, 45, 52, 58, 59, and 68. This study provides valuable insights into the prevalence, distribution, and epidemiological characteristics of HPV infections in a large population. It also highlights the potential impact of the COVID-19 pandemic on HPV trends.

show abstract

“…HPV oncogenicity is primarily dependent on the continuous expression and activity of the viral proteins E6 and E7, which are tumor-associated antigens that act in concert to alter interrelated cellular processes and promote tumor development through the interaction of cellular proteins. Because most HPV infections do not have an obvious clinical symptom, estimates of prevalence and incidence are important to understand the full burden of infection 9 . Although most HPV infections clear up on their own and most pre-cancerous lesions resolve spontaneously, there is a risk for all women that HPV infection can become chronic and pre-cancerous lesions progress to invasive cervical cancer 10 .…”

Section: Introductionmentioning

confidence: 99%

Prevalence of human papillomavirus infection and associated factors among women attending cervical cancer screening in setting of Addis Ababa, Ethiopia

Tesfaye,

Kumbi,

Mandefro

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Human papillomaviruses (HPVs) are circular, nonenveloped small double-stranded DNA viruses that infect stratified epithelium and can cause a number of life-threatening diseases. HPV is the central risk factor for developing cervical cancer and is estimated that approximately 98% of this disease is associated with oncogenic types of HPV. HPV infection leads to an estimated 266,000 cervical cancer deaths annually. Therefore, the objective of this study was to determine the prevalence of HPV infection and risk factors associated with cervical lesion among women attending the cervical cancer screening clinic at the Ethiopian Family Guidance Association, Addis Ababa. A cross-sectional study was conducted to determine the prevalence of HPV infection. Data were collected using a questionnaire and samples leftover from cervical screening were taken. The leftover swab was air dried and DNA was extracted and amplified by using a PCR. A total of 247 women were included in the study. The prevalence of HPV was 9.72% among the population studied. Of all participants, 27.13% were positive for cervical intraepithelial neoplasia-1 (CIN1). CIN1 positivity was found in half of HPV positive women. Among HPV positive women, half of them had started sexual intercourse at ages 12–17 years and 41.66% were women who gave birth at ages 12–17 years. The high prevalence of HPV and the CIN1 positive group were ages 36–57 and women with multiple sexual partners. The other groups with the highest CIN1 positive were 22.39% grade (9–12) and 20.9% primary (1–8) and uneducated women. Among HPV positive women, 83.33% had an abortion history and 80% miscarried in the first trimester. Among the CIN1 positives, 53.73% had more than two sexual partners. Among HPV positive women, half of them were users of contraception methods. In conclusion, the highest prevalence of HPV is among women who began sexual intercourse earlier and who gave birth at 12–17 years of age, have an abortion history, with MSP and oral contraceptive methods users. In addition to HPV, early pregnancy and sexual intercourse at 12–17 years of age, abortion, MSP, and oral hormonal contraceptives are factors in cervical cancer. Finally, most women do not have enough knowledge and awareness about cervical cancer and the risk factor.

show abstract

The prevalence of human papillomavirus among women in northern Guangdong Province of China

Cited by 12 publications

References 32 publications

Prevailing of HPV-16 and 52 genotype in 2022–2023 in Sanandaj, Iran

Prevailing of HPV-16 and 52 genotype in 2022–2023 in Sanandaj, Iran

Prevalence and genotype distribution of HPV infection from Hangzhou of Zhejiang Province pre- and during COVID-19 pandemic

Prevalence of human papillomavirus infection and associated factors among women attending cervical cancer screening in setting of Addis Ababa, Ethiopia

Contact Info

Product

Resources

About